• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢附件报告和数据系统、卵巢恶性肿瘤风险算法及哥本哈根指数在卵巢癌术前预测中的诊断性能:一项前瞻性队列研究。

Diagnostic performances of the Ovarian Adnexal Reporting and Data System, the Risk of Ovarian Malignancy Algorithm, and the Copenhagen Index in the preoperative prediction of ovarian cancer: a prospective cohort study.

作者信息

Vo Thi Quynh Nhu, Tran Doan Tu, Nguyen Tran Thao Nguyen, Vo Van Duc, Le Minh Tam, Nguyen Vu Quoc Huy

机构信息

Department of Obstetrics and Gynecology, Hue University of Medicine and Pharmacy, Hue University, Hue, Vietnam.

出版信息

J Gynecol Oncol. 2025 Mar;36(2):e30. doi: 10.3802/jgo.2025.36.e30. Epub 2024 Sep 24.

DOI:10.3802/jgo.2025.36.e30
PMID:39344149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11964957/
Abstract

OBJECTIVE

This study aimed to assess the diagnostic performance of the Risk of Ovarian Malignancy Algorithm (ROMA), Copenhagen Index (CPH-I), and Ovarian Adnexal Reporting and Data System (O-RADS) for the preoperative prediction of ovarian cancer (OC).

METHODS

A prospective cohort study was conducted on 462 patients diagnosed with ovarian tumors admitted to the Departments of Obstetrics and Gynecology, Hue University of Medicine and Pharmacy Hospital, and Hue Central Hospital from May 2020 to December 2022. ROMA and CPH-I were calculated using cancer antigen 125 (CA125), human epididymal protein 4 (HE4) levels, and patient characteristics (age and menopausal status). O-RADS criteria were applied to describe ovarian tumor characteristics from ultrasound findings. Compared with histopathological results, the predictive values of ROMA, CPH-I, and O-RADS alone or in combination with CA125/HE4 for OC were calculated.

RESULTS

Among 462 patients, 381 had benign tumors, 11 had borderline tumors, and 50 had OC. At optimal cut-off points, ROMA's and CPH-I's areas under the curves (AUCs) were 0.880 (95% confidence interval [CI]=0.846-0.909) and 0.890 (95% CI=0.857-0.918), respectively, and ROMA and CPH-I sensitivities/specificities (Se/Sp) were 68.85%/95.01% and 77.05%/91.08%, respectively. O-RADS ≥3 yielded an AUCs of 0.949 (95% CI=0.924-0.968), with Se/Sp of 88.52%/88.98% (p<0.001). Combining O-RADS with CA125 demonstrated the highest predictive value, with AUCs of 0.969 (95% CI=0.949-0.983) and Se/Sp of 98.36%/86.09% (p<0.001).

CONCLUSION

The ROMA, CPH-I, O-RADS, O-RADS + CA125, and O-RADS + HE4 models demonstrated good predictive values for OC; the combination of O-RADS and CA125 yielded the highest values.

摘要

目的

本研究旨在评估卵巢恶性肿瘤风险算法(ROMA)、哥本哈根指数(CPH-I)和卵巢附件报告与数据系统(O-RADS)对卵巢癌(OC)术前预测的诊断性能。

方法

对2020年5月至2022年12月在顺化医科大学药学院医院和顺化中央医院妇产科收治的462例诊断为卵巢肿瘤的患者进行了一项前瞻性队列研究。使用癌抗原125(CA125)、人附睾蛋白4(HE4)水平及患者特征(年龄和绝经状态)计算ROMA和CPH-I。应用O-RADS标准根据超声检查结果描述卵巢肿瘤特征。与组织病理学结果相比,计算ROMA、CPH-I和O-RADS单独或与CA125/HE4联合用于OC的预测值。

结果

462例患者中,381例为良性肿瘤,11例为交界性肿瘤,50例为OC。在最佳截断点时,ROMA和CPH-I的曲线下面积(AUC)分别为0.880(95%置信区间[CI]=0.846-0.909)和0.890(95%CI=0.857-0.918),ROMA和CPH-I的敏感度/特异度(Se/Sp)分别为68.85%/95.01%和77.05%/91.08%。O-RADS≥3的AUC为0.949(95%CI=0.924-0.968),Se/Sp为88.52%/88.98%(p<0.001)。将O-RADS与CA125联合显示出最高预测价值,AUC为0.969(95%CI=0.949-0.983),Se/Sp为98.36%/86.9%(p<0.001)。

结论

ROMA、CPH-I、O-RADS、O-RADS+CA125和O-RADS+HE4模型对OC均显示出良好预测价值;O-RADS与CA125联合的预测价值最高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4818/11964957/c8289737b869/jgo-36-e30-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4818/11964957/6f38e872f840/jgo-36-e30-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4818/11964957/c8289737b869/jgo-36-e30-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4818/11964957/6f38e872f840/jgo-36-e30-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4818/11964957/c8289737b869/jgo-36-e30-g002.jpg

相似文献

1
Diagnostic performances of the Ovarian Adnexal Reporting and Data System, the Risk of Ovarian Malignancy Algorithm, and the Copenhagen Index in the preoperative prediction of ovarian cancer: a prospective cohort study.卵巢附件报告和数据系统、卵巢恶性肿瘤风险算法及哥本哈根指数在卵巢癌术前预测中的诊断性能:一项前瞻性队列研究。
J Gynecol Oncol. 2025 Mar;36(2):e30. doi: 10.3802/jgo.2025.36.e30. Epub 2024 Sep 24.
2
Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study.哥本哈根指数与 ROMA 在术前卵巢恶性肿瘤风险分层中的比较:来自越南首个前瞻性队列研究的结果。
Gynecol Oncol. 2021 Jul;162(1):113-119. doi: 10.1016/j.ygyno.2021.05.001. Epub 2021 May 14.
3
CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.CPH-I 和 HE4 在鉴别早期交界性卵巢肿瘤与上皮性卵巢癌方面优于 CA125。
Dis Markers. 2019 Oct 13;2019:6241743. doi: 10.1155/2019/6241743. eCollection 2019.
4
[Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].血清癌抗原125、人附睾蛋白4、ROMA及CPH-I在中国卵巢肿物患者中诊断卵巢癌的比较
Nan Fang Yi Ke Da Xue Xue Bao. 2019 Dec 30;39(12):1393-1401. doi: 10.12122/j.issn.1673-4254.2019.12.02.
5
Diagnostic performance of CA125, HE4, ROMA, and CPH-I in identifying primary ovarian cancer.CA125、HE4、ROMA和CPH-I在识别原发性卵巢癌中的诊断性能。
J Obstet Gynaecol Res. 2023 Mar;49(3):998-1006. doi: 10.1111/jog.15540. Epub 2023 Jan 6.
6
A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.一种结合人附睾蛋白4(HE4)、癌抗原125(CA125)和年龄的新型诊断指标可能改善疑似卵巢癌女性的分诊——一项针对有卵巢肿物女性的国际多中心研究。
Gynecol Oncol. 2015 Sep;138(3):640-6. doi: 10.1016/j.ygyno.2015.06.021. Epub 2015 Jun 16.
7
Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.评估 HE4、CA125、卵巢恶性肿瘤风险算法(ROMA)和恶性肿瘤指数(RMI)在盆腔肿块患者中作为上皮性卵巢癌的诊断工具。
Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.
8
Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.上皮性卵巢癌患者卵巢恶性肿瘤风险的诊断措施比较:一项荟萃分析。
Sci Rep. 2021 Aug 27;11(1):17308. doi: 10.1038/s41598-021-96552-9.
9
Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?比较哥本哈根指数(CPH-I)和卵巢恶性肿瘤风险算法(ROMA):在手术前区分良恶性卵巢肿瘤的两种等效方法?
Gynecol Oncol. 2016 Mar;140(3):481-5. doi: 10.1016/j.ygyno.2016.01.023. Epub 2016 Jan 26.
10
The use of CA125, human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), risk of malignancy index (RMI) and subjective assessment (SA) in preoperative diagnosing of ovarian tumors.CA125、人附睾蛋白 4(HE4)、卵巢恶性肿瘤风险算法(ROMA)、恶性肿瘤指数(RMI)和主观评估(SA)在卵巢肿瘤术前诊断中的应用。
Ginekol Pol. 2024;95(5):321-327. doi: 10.5603/GP.a2022.0144. Epub 2023 Jan 4.

本文引用的文献

1
Copenhagen index (CPH-I) is more favorable than CA125, HE4, and risk of ovarian malignancy algorithm (ROMA): Nomogram prediction models with clinical-ultrasonographic feature for diagnosing ovarian neoplasms.哥本哈根指数(CPH-I)比CA125、人附睾蛋白4(HE4)以及卵巢恶性肿瘤风险算法(ROMA)更具优势:基于临床超声特征的列线图预测模型用于诊断卵巢肿瘤。
Front Surg. 2023 Jan 13;9:1068492. doi: 10.3389/fsurg.2022.1068492. eCollection 2022.
2
Does Combing O-RADS US and CA-125 Improve Diagnostic Accuracy in Assessing Adnexal Malignancy Risk in Women With Different Menopausal Status?联合使用O-RADS超声检查和CA-125能否提高评估不同绝经状态女性附件恶性肿瘤风险的诊断准确性?
J Ultrasound Med. 2023 Feb;42(3):675-685. doi: 10.1002/jum.16065. Epub 2022 Jul 26.
3
Diagnostic Performance of the Ovarian-Adnexal Reporting and Data System (O-RADS) Ultrasound Risk Score in Women in the United States.美国女性卵巢-附件报告和数据系统(O-RADS)超声风险评分的诊断性能。
JAMA Netw Open. 2022 Jun 1;5(6):e2216370. doi: 10.1001/jamanetworkopen.2022.16370.
4
Comparison of the O-RADS and ADNEX models regarding malignancy rate and validity in evaluating adnexal lesions.比较 O-RADS 和 ADNEX 模型在评估附件病变中的恶性率和有效性。
Eur Radiol. 2022 Nov;32(11):7854-7864. doi: 10.1007/s00330-022-08803-6. Epub 2022 May 18.
5
External Validation of O-RADS US Risk Stratification and Management System.O-RADS US 风险分层和管理系统的外部验证。
Radiology. 2022 Jul;304(1):114-120. doi: 10.1148/radiol.211868. Epub 2022 Apr 19.
6
Clinical value of O-RADS combined with serum CA125 and HE4 for the diagnosis of ovarian tumours.O-RADS联合血清CA125和HE4在卵巢肿瘤诊断中的临床价值
Acta Radiol. 2023 Feb;64(2):821-828. doi: 10.1177/02841851221087376. Epub 2022 Mar 15.
7
A comparison of the diagnostic performance of the O-RADS, RMI4, IOTA LR2, and IOTA SR systems by senior and junior doctors.资深医生和初级医生对O-RADS、RMI4、IOTA LR2和IOTA SR系统诊断性能的比较。
Ultrasonography. 2022 Jul;41(3):511-518. doi: 10.14366/usg.21237. Epub 2022 Jan 31.
8
Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses.IOTA 简单规则、O-RADS 和 CA125 对鉴别附件区良恶性肿块的效能。
J Ovarian Res. 2022 Jan 23;15(1):15. doi: 10.1186/s13048-022-00947-9.
9
Comparison of O-RADS, GI-RADS, and ADNEX for Diagnosis of Adnexal Masses: An External Validation Study Conducted by Junior Sonologists.O-RADS、GI-RADS和ADNEX在附件肿物诊断中的比较:初级超声科医生进行的外部验证研究
J Ultrasound Med. 2022 Jun;41(6):1497-1507. doi: 10.1002/jum.15834. Epub 2021 Sep 21.
10
Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women.IOTA简易规则、简易规则风险评估、ADNEX模型和O-RADS在北美女性附件区良恶性病变鉴别中的表现
Ultrasound Obstet Gynecol. 2022 May;59(5):668-676. doi: 10.1002/uog.24777. Epub 2022 Apr 8.